| Literature DB >> 21208438 |
Ching-Yu Lee1, Liang-Tseng Kuo, Kuo-Ti Peng, Wei-Hsiu Hsu, Tsan-Wen Huang, Ying-Chao Chou.
Abstract
BACKGROUND: Monomicrobial necrotizing fasciitis is rapidly progressive and life-threatening. This study was undertaken to ascertain whether the clinical presentation and outcome for patients with this disease differ for those infected with a gram-positive as compared to gram-negative pathogen.Entities:
Mesh:
Year: 2011 PMID: 21208438 PMCID: PMC3022716 DOI: 10.1186/1471-2334-11-5
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Group comparison of characteristics (Table 1)
| Gram positive pathogen (n = 11) | Gram Negative pathogen (n = 35) | p value | |
|---|---|---|---|
| Age | 59 (34, 72) | 64(22, 85) | 0.138 |
| Gender(Male/Female) | 9/2 | 26/9 | 1.000 |
| Involved region | |||
| Upper extremity | 5 (45.5) | 10 (28.6) | 0.462 |
| Lower extremity | 6 (54.5) | 25 (71.4) | |
| TiOA(day) | 7.18 (2, 14) | 2.43 (0.5, 14)* | < 0.001 |
| TiOS(hour) | 25.64 (2, 72) | 11.74 (1, 72)* | 0.046 |
| Immunocompromised(DM, liver dysfunction, Chronic renal failure, Malignancy) | 5 (45.5) | 29 (82.8)* | 0.022 |
| Comorbidity | |||
| DM | 5 (45.5) | 13 (37.1) | 0.728 |
| Gout | 5 (45.5) | 2 (5.7)* | 0.005 |
| Chronic renal failure (> 1.6 mg/dL) | 2 (18.2) | 7 (20) | 1.000 |
| Chronic Liver dysfunction | 1 (9.1) | 18 (51.4)* | 0.016 |
| HBV | 0 (0) | 11 (31.4)* | 0.044 |
| HCV | 1 (9.1) | 11 (31.4) | 0.241 |
| HBV or HCV | 1 (9.1) | 17 (48.6)* | 0.032 |
| Liver cirrhosis | 0 | 8 (22.9) | 0.619 |
| ICU stay(patient number) | 4 (36.4) | 26 (74.3)* | 0.032 |
| Post-operative mechanical ventilation (patient number) | 4 (36.4) | 24 (68.6) | 0.080 |
| APACHE II score | 12.9 (3, 21) | 18.9 (2, 34)* | 0.015 |
| ICU stay (day) | 2 (0, 7) | 4.3 (0, 16) | 0.077 |
| Hospital stay (day) | 35.7 (15, 70) | 35.8 (13, 87) | 0.800 |
| Amputation | 0 | 5 (10.9) | 0.317 |
| STSG | 5 (45.5) | 21 (60) | 0.494 |
| Free flap transfer | 1 (9.1) | 7 (20) | 0.658 |
| Mortality | 1(9.1) | 6(17.1) | 1.000 |
Data are presented as median (min, max) or frequency (%)
TiOA: duration of symptoms prior to arrival in the ER
TiOS: time of the first surgical intervention from arrival in the ER
APACHE: Acute Physiological, Age, and Chronic Health Evaluation
Chronic liver dysfunction: liver cirrhosis, viral hepatitis(HBV, or HCV)
STSG: split thickness skin graft
*: The difference is significant (p < 0.05)
Summary of microbiology
| Gram positive pathogen (n = 11) | |
|---|---|
| Staphylococcus aureus | 6(54.5%) |
| MSSA | 4 |
| MRSA | 2 |
| Streptococcus sp. | |
| Alpha-hemolytic | 1(9.1%) |
| | 1 |
| Beta-hemolytic | 4(36.3%) |
| | 1 |
| Group B | 3 |
| 23(66%) | |
| Vibrio vulnificus | 20 |
| Vibrio parahaemolyticus | 2 |
| Vibrio cholerae non-O1 | 1 |
| 8(23%) | |
| Aeromonas hydrophila | 6 |
| Aeromonas sobria | 1 |
| Aeromonas caviae | 1 |
| 1 | |
| 1 | |
| 1 | |
| | 1 |
Data are presented as frequency (%)
MRSA: Methicillin-Resistant Staphylococcus aureus
MSSA: Methicillin-Sensitive Staphylococcus aureus
Group comparison of signs and symptoms
| Symptoms and signs | Gram positive pathogen (n = 11) | Gram negative Pathogen (n = 35) | p-value |
|---|---|---|---|
| Fever (> 38.3°C) | 8 (72.7) | 16 (45.7) | 0.171 |
| Hypothemia (< 35°C) | 1 (9.0) | 4(11.4) | 1 |
| Pain and tenderness | 11 (100) | 35 (100) | 1 |
| Swelling and erythema | 11 (100) | 35 (100) | 1 |
| Hemorrhagic bullae | 0 (0) | 15 (42.9)* | 0.009 |
| Shock(< 90 mmHg) | 2 (18.2) | 23 (65.7)* | 0.013 |
| Inotropic support | 2 (18.2) | 19 (54.3)* | 0.045 |
Data are presented as frequency (%)
*: The difference is significant (p < 0.05)
Group comparison of laboratory data
| Laboratory data | Gram positive pathogen (n = 11) | Gram Negative pathogen (n = 35) | p-value |
|---|---|---|---|
| Leukocytosis(> = 12,000/ul) | 8 (72.7) | 23 (65.7) | 1.000 |
| Leukopenia(< = 4,000/ul) | 0 | 4 (11.4) | 0.559 |
| Leukocytosis or leukopenia | 8 (72.7) | 27 (77.1) | 1.000 |
| Band formation | 9 (81.8) | 33 (94.3) | 0.238 |
| Band ≧ 10% | 3 (27.3) | 16 (45.7) | 0.320 |
| neutrophilia(> 7,500/ul) | 8 (72.7) | 25 (71.4) | 1.000 |
| Lymphocytopenia(< 1,000/ul) | 2 (18.2) | 19 (54.3)* | 0.045 |
| 0 | 12 (34.3)* | 0.044 | |
| 7 (63.6) | 17 (48.6) | 0.497 | |
| 12.4 (10.0, 14.1) | 12.6 (7.7, 15.8) | 0.690 | |
| 178.0 (50, 373) | 114.0 (24.4, 354) | 0.302 | |
| 265.4 (121, 842) | 164.14(91, 436) | 0.065 | |
| 132.4 (124, 136) | 135.3 (127, 141)* | 0.044 | |
| 6 (54.5) | 24 (68.6) | 0.477 | |
| 6.18 (4, 10) | 4.51 (0, 12)* | 0.031 |
Data are presented as median (min, max) or frequency (%)
Chronic liver dysfunction: liver cirrhosis, viral hepatitis (HBV, or HCV)
LRINEC: Laboratory Risk Indicator for Necrotizing Fasciitis
*: The difference is significant (p < 0.05)
Comparison of characteristics between survivals and deaths
| Survivors(n = 39) | Deaths (n = 7) | p value | |
|---|---|---|---|
| 62 (22, 85) | 68 (55, 78) | 0.668 | |
| Male | 30 (76.9) | 6 (85.7) | 1.000 |
| Female | 9 (23.1) | 1 (14.3) | |
| Viral hepatitis | 13 (33.3) | 5 (71.4) | 0.093 |
| Liver cirrhosis | 4 (10.2) | 4 (57.1)* | 0.012 |
| Chronic liver dysfunction | 13 (33.3) | 6 (85.7)* | 0.015 |
| Diabetes mellitus | 16 (41.0) | 2 (28.6) | 0.688 |
| Chronic renal failure | 5 (12.8) | 4 (57.1)* | 0.020 |
| 27 (69.2) | 7 (100) | 0.165 | |
| Gram positive pathogen | 10 (25.6) | 1 (14.3) | 0.667 |
| Gram negative pathogen | 29 (74.4) | 6 (85.7) | |
| Upper extremity | 11 (28.2) | 4 (57.1) | 0.193 |
| Lower extremity | 28 (71.8) | 3 (42.9) | |
| 19 (48.7) | 6 (85.7) | 0.106 |
Data are presented as median (min, max) or frequency (%)
Chronic liver dysfunction: liver cirrhosis, viral hepatitis (HBV, or HCV)
*: The difference is significant (p < 0.05)
Comparison of laboratory data between survivals and deaths
| Survival n = 39 | non-survival n = 7 | p-value | |
|---|---|---|---|
| Leukocytosis(> 12,000/ul) | 27 (69.2) | 4 (57.1) | 0.667 |
| Leukopenia(< 4,000/ul) | 2 (5.1) | 2 (28.6) | 0.104 |
| Leukocytosis or leukopenia | 29 (74.3) | 6 (85.7) | 0.667 |
| Band formation | 35 (89.7) | 7 (100) | 1.000 |
| neutrophilia(> 7,500/ul) | 29 (74.3) | 4 (57.1) | 0.385 |
| lymphocytopenia(< 1,000/ul) | 16 (41.0) | 5 (71.4) | 0.220 |
| 7 (17.9) | 5 (71.4) | 0.009 | |
| 12.6 (7.7, 15.8) | 12.4 (10.0, 14.7) | 0.866 | |
| 135 (50, 373) | 97 (63, 227) | 0.915 | |
| 194.9 (90, 842) | 152 (105, 264) | 0.667 | |
| 134.6(124, 141) | 134.4 (127, 140) | 0.988 | |
| 5 (12.8) | 4 (57.1)* | 0.020 | |
| 22 (56.4) | 7 (100)* | 0.036 | |
| 5.1 (0, 12) | 3.7 (0, 70 | 0.217 | |
| APACHE II | 16.9 (2, 34) | 21.3 (17, 27) | 0.090 |
| ICU stay (patient numbers) | 23 (59.0) | 7 (100) | 0.078 |
| post-OP ventilator (patient numbers) | 21 (53.8) | 7 (100)* | 0.032 |
| ICU stay (day) | 2.5 (0, 16) | 10.3 (7, 14)* | < 0.001 |
| Hospital stay(day) | 36 (13, 87) | 34.6 (14, 79) | 0.635 |
Data are presented as median (min, max) or frequency (%)
APACHE, acute physiological, age, and chronic health evaluation
Chronic liver dysfunction: liver cirrhosis, viral hepatitis(HBV, or HCV)
*: The difference is significant (p < 0.05)